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Summary
Objective: To examine the role of mitogen-activated protein kinase-activated protein kinase 2 (MK2) in mediating the cellular response to
pro-inﬂammatory cytokines in human primary osteoarthritis (OA) chondrocytes.
Methods: Delivery of a dominant negative MK2 was achieved in HeLa cells by adenoviral infection. Cellular heat shock protein (HSP27)
activity was determined using a Bioplex assay. Primary OA chondrocytes were isolated by collagenase digestion of human articular cartilage.
Phosphorylated MK2 was detected by immunoblotting and immunohistology. Transfection of primary chondrocytes with siRNA was achieved
using cationic lipid and gene expression determined by real-time polymerase chain reaction. Production of prostaglandin E2 (PGE2) and ma-
trixmetalloproteases (MMPs) was measured by enzyme-linked immunosorbent assay.
Results: Over-expression of a dominant negative MK2 inhibited HSP27 phosphorylation and signiﬁcantly reduced both interleukin 1 (IL-1)b
and tumour necrosis factor (TNF)-a mediated release of PGE2 in HeLa cells over a 24 h period. Phosphorylated MK2 was detected in OA
articular cartilage and in isolated primary OA chondrocytes, where it was induced by IL-1b. Transfection of OA chondrocytes with MK2 siRNA
antisense signiﬁcantly reduced both basal and IL-1b induced PGE2 release. siRNA mediated MK2 knockdown also signiﬁcantly reduced both
basal and IL-1b induced MMP13 expression and MMP13 and MMP3 protein release but had no effect on MMP1.
Conclusions: Our data reveal that MK2 is active in OA human articular cartilage and in isolated primary human chondrocytes and that MK2
mediates the release of PGE2, MMP3 and MMP13. These ﬁndings suggest a role for MK2 in contributing to OA algesia and OA joint structural
deterioration by mediating the downstream effects of p38 activation on PGE2 release and the expression and release of catabolic proteases.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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There is increasing evidence that osteoarthritis (OA)
consists of an inﬂammatory component. Magnetic reso-
nance imaging, immunohistochemical studies and ultraso-
nography have all demonstrated synovitis in early OA1e3,
with mononuclear cell inﬁltration, and the production of
pro-inﬂammatory cytokines and mediators of joint dam-
age4,5. Furthermore, recent evidence has demonstrated
a correlation between the degree of synovitis and knee
pain6 suggesting that inﬂammatory mediators may contrib-
ute to OA pain either by direct stimulation of primary afferent
peripheral nociceptive ﬁbres or by sensitisation7e9.
A key signalling pathway in mediating this inﬂammation is
thought to be the p38 mitogen-activated kinase (MAPK)
pathway. Previous studies suggest that p38 MAPK
regulates not only pro-inﬂammatory cytokine production
(TNF-a, IL-1b and IL-6) but also the downstream effect of
these cytokines on target cells. Importantly a number of*Address correspondence and reprint requests to: Dr Simon W.
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124observations suggest that the degree of p38 pathway acti-
vation is elevated in OA disease. Firstly, active, phosphor-
ylated p38 is detectable in OA chondrocytes and in OA
articular cartilage and is elevated in response to culprit
drivers of OA such as IL-1b, TNF-a10, mechanical stimuli11
and ﬁbronectin fragments12 which are found in the synovial
ﬂuid of OA patients. In support of this, inhibition of the p38
pathway in pre-clinical models of OA attenuates structural
progression and modiﬁes behavioural indices of pain. In
the rat mono-iodoacetate model of articular joint destruction
and algesia, p38 inhibition was effective in reducing altered
weight-bearing behaviour and macroscopic cartilage lesion
degeneration13. Similarly, in animal models of rheumatoid
arthritis (collagen induced arthritis model and streptococcal
cell wall models), administration of p38 inhibitors also
reduces cartilage loss and is anti-hyperalgesic14e16. At
the cellular level, p38 inhibitors have been shown to reduce
the release of the catabolic protease matrixmetalloprotease
(MMP)13 in human chondrocytes17 and in both chondro-
cyte cells and cartilage explant tissue an inhibitor of p38
has been shown to inhibit the IL-1b induction of prostaglan-
din E (PGE) synthase and the production of PGE218,19.
However, the mechanism by which these downstream
effects are mediated, particularly in human cells, remains
unclear but is likely to be both cell type and signal
125Osteoarthritis and Cartilage Vol. 17, No. 1dependent and involves the transduction of signals to target
cells via downstream MAPK-activated protein kinases
(MAPKAPKs).
MAPKAPK2 (MK2) is one of several kinases directly
activated by p38 MAPK20. Previous studies using MK2
knockout mice in order to determine the physiological role
of MK2 have demonstrated that MK2 regulates the stability
and translation of TNF-a, and that MK2 is essential for
the lipopolysaccharide (LPS)-induced production of TNF-
a21,22. It has been proposed that this post-transcriptional
regulation of TNF-a production may involve the MK2 sub-
strate tristetraprolin (TTP), an adenine rich element (ARE)-
emRNA binding protein, which has been shown to
modulate TNF-a mRNA stability23,24. Similar knockout stud-
ies involving other kinases downstream of p38 such as
MK5/PRAK, Msk1/2, and Mnk1/2 have failed to show
such an effect, suggesting MK2 is a key mediator of selec-
tive p38 mediated pro-inﬂammatory responses20. Further-
more, given the role of MK2 in the post-transcriptional
regulation of TNF-a it would seem plausible that other
ARE containing transcripts such as MMP13 and COX2
are also subjected to MK2 post-transcriptional control. In-
deed, it has been shown that over-expression of a constitu-
tively active MK2 in HeLa cells was able to stabilise COX2
transcript stability, and that stabilisation of COX2 transcripts
was blocked by transfection with two different dominant
negative forms of MK225.
Therefore, selective targeted inhibition of the p38 path-
way could potentially be an effective therapeutic strategy
for disease modiﬁcation and in providing pain relief in OA.
In this study we have examined the association of active
MK2 (as reported by the detection of phosphorylated
MK2) with OA cartilage and the role of MK2 in mediating
the pro-inﬂammatory cytokine-induced effect of p38 activa-
tion in human cells, in particular, in human primary OA
chondrocytes. Here we demonstrate that MK2 is active in
OA chondrocytes and that the IL-1b induced production of
MMP13, MMP3 and PGE2 is mediated by MK2.MethodsPREPARATION OF PRIMARY CHONDROCYTESHuman OA cartilage was obtained from patients undergoing total knee
replacement operations whilst normal cartilage was taken from postmortem
donors with no previous history of joint pain. Donors were male, aged 50e70
and the OA donors were taking pain relief medication (e.g., paracetamol or
ibuprofen). Full ethical consent was obtained from all donors and families.
To isolate primary chondrocytes, slices of cartilage were stripped from the
femoral condyles and tibial plateaux, cut into small pieces using a scalpel
blade and digested in growth media [dulbecco’s modiﬁed eagles medium
(DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (100 units/
ml), streptomycin (100 mg/ml), 2 mM L-glutamine, non-essential amino acids (In-
vitrogen, Paisley, UK) and amphotericin (2.5 mg/ml)] containing 1%collagenase
type IA (0.5e3.0 furylacryloyl-Leu-Gly-Pro-Ala (FALGPA) units/mg, Sigma,
Dorset, UK). Following overnight incubation at 37C, the sample was ﬁltered
to remove undigested cartilage and chondrocyte cells pelleted at 2000g for
5 min before being resuspended in growth media. Primary cells were then
grown in monolayer without passaging until conﬂuent (approximately 14 days
from isolation) before being utilised in subsequent experiments.ADENOVIRAL INFECTION OF HeLa CELLS
WITH DOMINANT NEGATIVE MK2HeLa cells were seeded at 2 104 cells/well in a 96-well plate and grown
overnight at 37C before being infected (500:1 MOI) with either a dominant
negative MK226 (Cell Biolabs, San Diego, CA, USA; ADV-138), dominant
negative p38a (Cell Biolabs, ADV-105) or a GFP control adenovirus (Cell
Biolabs, ADV-004). After 24 h infection viral particles were removed and
the cells stimulated with either TNF-a (10 ng/ml) or IL-1b (10 ng/ml) for either
30 min for subsequent HSP27 analysis or for 24 h for analysis of PGE2
production.BIOPLEX DETERMINATION OF TOTAL AND PHOSPHO HSP27The Bioplex assay was performed according to the manufacturer’s proto-
col (Upstate Cell Signalling Solutions, VA, USA). In brief, a 96-well ﬁlter plate
was pre-wet with assay buffer and then 25 ml of either total or phospho
HSP27 (ser78) bead solution (Upstate) was added to each well together
with 25 ml of cell lysate (diluted in the appropriate assay buffer). Following
overnight incubation at 4C on a plate shaker the cell lysate was removed
by vacuum ﬁltration. The plate was then washed twice with assay buffer
before the addition of 25 ml of biotinylated reporter solution. The plate was
then incubated on a plate shaker for 1 h at room temperature whilst protected
from the light. The reporter was then removed by vacuum ﬁltration and 25 ml
of StreptavidinePhycoerthrin (StreptePE) added and the plate incubated on
a shaker for a further 30 min. Finally, the StreptePE was removed by vac-
uum ﬁltration, the beads resuspended in 100 ml of appropriate assay buffer
and analysed using the Luminex100 System. The degree of activated
HSP27 was expressed as phospho HSP27 relative to total HSP27.ANALYSIS OF PHOSPHORYLATED MK2 EXPRESSION IN
PRIMARY CHONDROCYTES AND ARTICULAR CARTILAGECartilage excised from OA and postmortem control knees (n¼ 4) was
powdered under liquid nitrogen (Freezer mill) and then homogenised using
a polytron in 3 vol of radioimmunoprecipitation assay RIPA buffer containing
protease inhibitor cocktail (Sigma) and a phosphatase inhibitor (Sigma). The
homogenate was then centrifuged at 10,000g for 10 min and the supernatant
lysate quantiﬁed for total protein essentially by the method of Bradford30
using a commercial kit (BioRad Laboratories, Hertfordshire, UK). Equal
amounts of total protein (80 mg) were then loaded onto a 4e12% sodium
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) gel
(Invitrogen, Paisley, UK) and run at a constant 30 mA for 2 h. Gels were blot-
ted onto polyvinylidene ﬂuoride membrane (GE Healthcare, Amersham Bio-
sciences) at 200 mA for 1 h, immunoprobed with phosphoMK2 (Thr334)
antibody (Cell Signalling) at a dilution of 1:100 and developed using ECLþ
(GE Healthcare, Buckinghamshire, UK).
Immunohistochemical staining of phosphorylated MK2 was performed on
frozen cartilage sections (7 mm thick) from knee OA and postmortem control
donors adhered to superfrost plus slides. Following ﬁxation in cold acetone
(10 min), endogenous peroxidase activity was blocked using a solution of
3% hydrogen peroxide in methanol. Following antigen retrieval with 0.5 mg/
ml hyaluronidase (Sigma) and a normal sheep serum (Serotec, Oxford, UK)
protein block, the slides were incubated with primary MK2 antibody (Thr334,
Cell Signalling Technology) overnight at 4C. Detection was achieved
using a biotinylated sheep anti-rabbit antibody (Serotec) and VectorStain
ABC kit (Dako, Denmark). Visualisation was performed using 3,
3-diaminobenzidine (DAB; Dako) with haematoxylin counterstain. The isotype
control was human adsorbed rabbit immunoglobulinG (IgG) (0.5 mg/ml; Dako).siRNA TRANSFECTION OF PRIMARY CHONDROCYTESHuman primary chondrocytes were transfected with four separate MK2
siRNA duplexes (Off Target Plus duplexes, Dharmacon, Lafayette, CO,
USA) or with a p38 siRNA at a ﬁnal concentration of 10 nM using 3 mg/ml
Atufect01 lipid (Silence Therapeutics, Atugen, London, UK). Efﬁcacy of trans-
fection was determined by measuring the effect on knockdown of MK2 expres-
sion relative to a non-targeting control (NTC) siRNA (Dharmacon). Following
48 h post-transfection, cells were stimulated for 24 h with IL-1b before condi-
tioned media were removed for protein analysis by enzyme-linked immunosor-
bent assay (ELISA) and the cells harvested for gene expression analysis.GENE EXPRESSION ANALYSIS IN PRIMARY
HUMAN CHONDROCYTESTotal RNA was extracted from primary human chondrocytes using the 96
Rneasy kit (Qiagen, Crawley, UK) according to the manufacturer’s instruc-
tions and then quantiﬁed using a Bioanalyser (Agilent, West Lothian, UK).
Taqman primers and probes were designed using Primer Express version
2.0 Software (PerkineElmer, Massachusetts, UK). Taqman probes were
labelled with a reporter dye, FAM (6-carboxyﬂuorescein), at the 50 end,
and a ﬂuorescent quencher dye TAMRA (6-carboxy-tetramethyl-rhodamine)
at the 30 end. Real-time polymerase chain reaction (RT-PCR) was performed
using the one-step RT-PCR kit (Qiagen) in a MicroAmp 96-well Reaction
Plate. Each well contained 25 ng total RNA, 300 nM (forward and reverse)
primers and 125 nM Taqman probe in a reaction volume of 25 ml. All sample
and non-template control reactions were performed in the ABI Prism 7700
Sequence Detection System (Applied Biosystems) in triplicate. For each
primer/probe set a series of standard curves was obtained using a standard
control sample of RNA. Comparative slopes of the relationship between log
[RNA] and Ct (gradient¼3.3) for both the gene of interest and the house-
keeping gene 18S indicated that the comparative Ct method (DDCt) could be
used for the relative quantiﬁcation of gene expression.
Fig. 1. The effect of over-expressing a dominant negative MK2 on activation of the MK2 pathway and the production of PGE2. HeLa cells were
infected using an adenovirus with a dominant negative mutant of MK2 (or green ﬂuorescent protein (GFP) control) for 24 h. Following infection,
cells were treated for 30 min with either IL-1b or TNF-a and the proportion of phosphorylated HSP27 relative to total HSP27 determined from
cell lysates (a). In a separate experiment HeLa cells were treated for 24 h with TNF-a or IL-1b following adenoviral infection with mutant MK2
or GFP and the production of PGE2 over a 24 h period determined by ELISA from cell supernatants (b). Cells not infected with adenovirus
were left for 24 h in cell culture media (CON) before cytokine addition. p38i refers to a small molecule adenosine triphosphate (ATP) binding
site p38a inhibitor (EC50¼ 5 nM in human acute monocytic leukemia cell line (THP)1 cells TNF-a ELISA). Bars are mean S.E.M. (n¼ 3).
*P< 0.05, signiﬁcantly different from corresponding control value.
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assayed for PGE2 protein using a commercially available ELISA kit (R&DSystems, Abingdon, UK; KGE004). MMP1 and MMP13 were determined in
primary chondrocytes using an in-house ELISA, and the levels of MMP3
determined using a commercially available kit (Duoset ELISA R&D Systems)
following the manufacturer’s instructions. For MMP1 and MMP3, polysytrene
Fig. 2. MK2 is active in human articular OA cartilage. (a) Frozen cartilage sections (7 mm thick) from knee OA and normal control donors were
immunoprobed with phosphorylated MK2 antibody (Thr334; Cell Signalling, 1:100) or an isotype control and stained with DAB using a haema-
toxylin counterstain. The isotype control was human adsorbed rabbit IgG (0.5 mg/ml; Dako) and was clear in all cases. (b) Immunoblot of
protein lysates (80 mg) extracted from frozen OA and normal human cartilage tissue (n¼ 4) and probed with anti-phosphoMK2 (Thr334;
1:250) and developed using enhanced chemiluminescence (ECLþ). The blot was scanned using a densitometer and mean phosphoMK2
quantity expressed in arbitrary denistometric units S.E.M. (n¼ 4).
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body (MMP1 R&D Systems MAB901; MMP13 R&D Systems MAB511) in
phosphate buffered saline (PBS) and left overnight at 4C. Following removal
of the coating antibody, the plates were washed three times with wash bufferFig. 3. IL-1b induces phosphorylation of MK2 in primary OA chon-
drocytes. Total protein was extracted from primary human OA
chondrocytes following stimulation with or without IL-1b (10 ng/ml)
for 15, 30 or 60 min. Following total protein determination, equal
total protein (80 mg) was analysed for by western blot using the
phosphoMK2 antibody (Thr334; 1:250). The immunoblot was
developed by ECL.(PBS containing 0.05% polysorbate) before the wells were blocked for 1e2 h
at room temperature with 100 ml/well of PBS containing 2% bovine serum al-
bumin (BSA). The plates were then washed as above, before the addition of
40 ml/well of sample or standard. In the case of MMP1, samples and stan-
dards were left on the plate for 2 h before being aspirated. The plate was
then washed as previously described before the addition of biotinylated
anti-MMP1 (R&D Systems; BAF901) for 2 h. The plate was then washed be-
fore the addition of horseradish peroxidase (HRP) substrate diluted 1:1000 in
PBS for 30 min. In the case of MMP13, 40 ml/well of a polyclonal MMP13 an-
tibody (Abcam; ab9128), diluted 1:2500 in PBS, was added together with
samples or standards before the plates were incubated for 2 h at room tem-
perature. Following plate washing, 40 ml/well of secondary anti-rabbit horse-
radish peroxidase (HRP) conjugate (GE Healthcare; NA934) was added and
the plate was incubated for a further 2 h.
All plates were developed with the addition of 40 ml/well of 3,30,5,50-
tetramethylbenzidine (TMB) for 20 min in the dark at room temperature,
and reactions stopped with the addition of H2SO4 (2 M) before the absorbance
read at 450 nm (Pherastar plate reader).STATISTICAL ANALYSISAll data are reported as means S.E.M. Comparisons were performed
using analysis of variance (ANOVA) and post hoc tests used to test for sig-
niﬁcance, with signiﬁcance accepted as P< 0.05.ResultsMK2 REGULATES THE RELEASE OF PGE2 IN HUMAN CELLSPrevious work has demonstrated that MK2 mediates the
post-translational regulation of COX225; thus, MK2 may reg-
ulate the production of PGE2. To explore the role of MK2 in
regulating PGE2 synthesis we over-expressed a dominant
Fig. 4. Reduction in MK2 mRNA expression using siRNA antisense.
(a) Expression of MK2 mRNA (normalised to 18S ) following 48 h
transfection in human primary OA chondrocytes with four different
MK2 siRNA (Dharmacon) or with NTC siRNA at 0, 1, 3, 10 or
30 nM. Bars are mean S.E.M. (n¼ 2). (b) Western blot using total
MK2 antibody (Cell Signalling) showing reduction in detectable
MK2 protein at 72 h post-transfection.
128 S. W. Jones et al.: MK2 modulates key biological pathways associated with OAnegative form of MK2 and examined the effect of disrupted
MK2 signalling on the IL-1b and TNF-a induced production
of PGE2 protein.
First of all, we conﬁrmed that TNF-a and IL-1b both
induced phosphorylation of the MK2 substrate HSP27 in
HeLa cells. As expected, the induction of HSP27 phosphor-
ylation either by stimulation of TNF-a or with IL-1b was sup-
pressed by an in-house small molecule p38 inhibitor.
However, importantly we also found that both the TNF-a
and IL-1b induction of HSP27 phosphorylation was similarly
reduced in HeLa cells over-expressing a dominant negative
form of MK2. Moreover, in those cells over-expressing the
dominant negative form of MK2 the IL-1b and TNF-a medi-
ated release of PGE2 over a 24 h period was signiﬁcantly
(P< 0.05) reduced [Fig. 1(a and b)].PHOSPHORYLATED MK2 IS PRESENT IN OA TISSUEFig. 5. The effect of MK2 siRNA on the production of PGE2 in
primary OA chondrocytes. Primary human OA chondrocytes were
transfected with the most efﬁcacious MK2 siRNA (duplex 4),
a p38 a siRNA or an NTC siRNA at 10 nM. Following 48 h transfec-
tion both basal (a) and IL-1b stimulated (b) production of PGE2 over
a 24 h period was determined by ELISA. Bars represent mean
S.E.M. (n¼ 3). *P < 0.05, **P < 0.01, signiﬁcantly different from
corresponding NTC siRNA value.MK2 kinase activity is signiﬁcantly enhanced following
phosphorylation of residues Thr222, Ser272 and Thr334
by p38. Thus, the detection of phosphorylated MK2 protein
in cells and tissues is indicative of active MK2. In order to
determine the activity of MK2 in human OA cartilage we
assayed the Thr334 phosphorylation status of MK2 in
human articular OA cartilage by both immunohistochemistry
(IHC) and by western blot analysis of cartilage protein
lysates [Fig. 2(a and b)]. Western blot analysis of OA and
normal postmortem cartilage protein lysate indicated an
increased abundance (approximately twofold) of phosphor-
ylated MK2 in OA cartilage compared to macroscopically
normal cartilage obtained postmortem from individuals
with no clinical diagnosis of OA [Fig. 2(a)]. Although this
was not statistically signiﬁcant the greater abundance of
phosphorylated MK2 in OA cartilage was supported by
IHC analysis of cartilage sections, where phosphorylatedMK2 was undetected in both normal donors tested but
strongly detectable in OA cartilage sections, especially in
areas of microscopic ﬁbrillation [Fig. 2(b)].MK2 IS ACTIVATED BY IL-1b AND MEDIATES THE PRODUCTION
OF PGE2 AND CATABOLIC PROTEASES IN OA
CHONDRCOYTESIL-1b is a candidate driver of catabolic and algesic pro-
cesses in OA and is a well established activator of the
p38 pathway. We, therefore, determined if stimulation of
primary OA chondrocytes with IL-1b led to activation of
MK2. We found that IL-1b stimulation of isolated primary
chondrocytes from OA articular cartilage led to an induction
in phosphorylated MK2. MK2 Thr334 phosphorylation was
maximal following 30 min of IL-1b stimulation (Fig. 3). Inter-
estingly, detection of MK2 Thr334 phosphorylation declined
back to base-line after 60 min exposure to IL-1b.
We next considered the effect of suppressing primary
chondrocyte MK2 on reporters of IL-1b driven algesic and
catabolic processes, namely PGE2 and MMP expression.
To achieve this we adopted an siRNA mediated gene-
knockdown approach. Lipid transfection of MK2 siRNA
duplexes into primary OA chondrocytes resulted in up to
a 95% reduction in MK2 mRNA at 48 h post-transfection
Fig. 6. The effect of MK2 siRNA on the production of catabolic proteases. Primary human OA chondrocytes were transfected with the most
efﬁcacious MK2 siRNA duplex (siMK2; duplex 4), a p38a siRNA (sip38) or an NTC siRNA (siNTC) at 10 nM (n¼ 3). Following 48 h transfection
both basal and IL-1b stimulated expression of MMP13 was determined by real-time PCR. Data were normalised to the housekeeping gene
18S and relative expression determined by the DDCT method (a). The effect of MK2 siRNA on the IL-1b induced production of both MMP13
and MMP3 protein was determined by ELISA from chondrocyte supernatants (b). **P< 0.01 signiﬁcantly different from corresponding NTC
siRNA value.
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expression at 72 h post-transfection [Fig. 4(b)].
Analysis of the supernatants transfected with the most
efﬁcacious MK2 siRNA duplex showed that knockdown of
MK2 expression led to a signiﬁcant reduction in both the
basal (P< 0.05) and the IL-1b mediated release of PGE2
(P< 0.01) compared to transfection with an NTC siRNA
[Fig. 5(a and b)]. There was also a reduction in IL-1b medi-
ated PGE2 release in cells transfected with a p38a siRNA
[Fig. 5(b)].
In determining the effect of MK2 knockdown on MMP
expression we found that transfection of human OA chon-
drocytes with MK2 siRNA signiﬁcantly reduced both basal
(P< 0.05) and also IL-1b mediated (P< 0.01) MMP13
expression [Fig. 6(a)]. The effect on reducing the IL-1b
driven induction of MMP13 expression was matched by
a p38 siRNA [Fig. 6(a)]. Analysis of MMP protein
[Fig. 6(b)] in the supernatants from OA chondrocytes trans-
fected with MK2 siRNA showed that knockdown of MK2
expression also led to a signiﬁcant reduction (P< 0.01) in
the IL-1b induced release of MMP13 protein (80% reduc-
tion) and to a lesser extent MMP3 protein (40% reduction).
Similar effects with regards to the inhibition of MMP13 pro-
tein production were observed with the p38a siRNA trans-
fection. However, of interest, there was a divergence of
effects with regards to the attenuation of MMP3 release:
siRNA mediated MK2 knockdown resulted in an approxi-
mate 40% inhibition, while siRNA mediated p38 knockdown
resulted in an approximate 80% inhibition. There was no
effect of MK2 knockdown on the release of MMP1 protein
(data not shown).Discussion
Understanding the mechanism of how the p38 MAPK
pathway mediates the downstream effects of pro-
inﬂammatory cytokines on target cells could help deﬁne
approaches for therapeutic intervention in inﬂammatory dis-
orders, including OA. Previously it has been demonstrated
that MK2, one of several MAPKAPKs’ downstream of p38,
mediates the production of TNF-a and thus it has been sug-
gested that MK2 may play a pivotal role in mediating selec-
tive downstream effects of p38 activation on target cells.
However, these ﬁndings were from studies using an MK2
knockout mouse and little has been published to date
regarding the role of MK2 in human cells.
In the present study we have demonstrated that MK2 is
active in human OA cartilage and that in human primary
chondrocytes MK2 mediates the release of PGE2, MMP3
and MMP13.
Using siRNA tools we found that the reduction in both
basal and IL-1b mediated MMP13 expression with MK2
siRNA was similar to that observed with a p38 siRNA. How-
ever, in contrast to the p38 siRNA, which was equally as
effective at inhibiting the release of either MMP3 or
MMP13, the MK2 siRNA was signiﬁcantly less effective at
inhibiting the release of MMP3. Indeed, it has previously
been reported that the p38 inhibitor SB203580 is equally
effective in inhibiting MMP3 as MMP13 in human chondro-
cytes27. This discrepancy between the efﬁcacy of the MK2
and p38 siRNA at inhibiting the release of MMP3 could be
explained by the possibility that other p38 substrates (in
addition to MK2) mediate MMP3 expression and thus
130 S. W. Jones et al.: MK2 modulates key biological pathways associated with OAreducing p38 expression impacts on MMP3 via multiple
pathways. If true this would suggest that more selective
MMP inhibition (i.e., speciﬁc inhibition of MMP13) could
be better achieved by direct targeting of MK2, which is
known to regulate transcripts, which contains adenine rich
elements such as MMP13.
Previous studies have proposed the use of p38 inhibitors
as chondroprotective compounds in part due to their effects
on inhibiting both the expression and release of MMPs17,27
and inhibiting the production of PGE217 in human chondro-
cytes. However, one of the potential drawbacks in the use
of p38 inhibitors as therapeutic compounds is the central
role of p38 MAPK in multiple downstream signalling
cascades, an issue highlighted by the reports of pro-
inﬂammatory as well as anti-inﬂammatory effects trans-
duced dependent on the cell type28 and the fact that p38
inhibitors have not progressed past Phase II clinical trials.
Importantly, the ﬁndings of the present study would suggest
that these potentially chondroprotective effects could be
more selectively achieved through direct inhibition of MK2
activity. Furthermore, despite the p38 siRNA duplex being
similarly as efﬁcacious as the MK2 siRNA with respect to
gene expression knockdown, the data showed that with
respect to the downstream effect on the production of
PGE2 that the MK2 siRNA was more efﬁcacious. This could
be explained by the MK2 siRNA impacting on the MAPK
pathway further downstream and, therefore, closer to the
biological end-point assay and might suggest that therapeu-
tic intervention targeting one of the MAPKAPKs’ downstream
of p38 MAPK might be a more efﬁcacious approach for
inhibition of PGE2. However, caution must be taken when
considering such extrapolations as the kinetics of p38 and
MK2 activation/de-activation in chondrocytes and the efﬁ-
cacy/duration of siRNA suppression vs p38 and MK2 has
not been fully characterised.
Taken together these ﬁndings suggest that MK2 may play
a pivotal role in mediating the production of catabolic prote-
ases and the release of PGE2 in OA cartilage tissue and im-
ply that therapeutic modulation of MK2 activity could lead to
chondroprotective effects. However, it remains to be deter-
mined in vivo, whether a reduction in MK2 activity will lead
to a compensatory increase in expression and/or activity of
MK3 given the previous observation that MK3 and MK2
have overlapping functions in vitro and that over-expression
of MK3 can rescue the phenotype of MK2-deﬁcient mice29.Conﬂict of interest
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